Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Novartis Ag
Novartis Ag_20100107
Novartis Ag And The Jackson Laboratory
Novartis Ag_20100114
Novartis Ag_20100121
Novartis Ag_20131212
Novartis Ag_20100128

Novartis Ag patents


Recent patent applications related to Novartis Ag. Novartis Ag is listed as an Agent/Assignee. Note: Novartis Ag may have other listings under different names/spellings. We're not affiliated with Novartis Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Novartis Ag-related inventors


Subretinal fluid drainage instruments, systems, and methods

A surgical instrument for removal of subretinal fluid is provided herein. The surgical instrument may include a handle coupleable to an aspiration source and a first elongate tubular member having a proximal end and a distal end, the proximal end being coupled to the rotational structure such that the first... Novartis Ag

Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.... Novartis Ag

Angiopoietin-like 4 antibodies and methods of use

The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.... Novartis Ag

Treatment of cancer using a cd33 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell... Novartis Ag

Car-expressing cells against multiple tumor antigens and uses thereof

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents... Novartis Ag

Silicone hydrogel lenses with water-rich surfaces

The invention is related to a hydrated silicone hydrogel contact lens having a layered structural configuration: a lower water content silicone hydrogel core (or bulk material) completely covered with a layer of a higher water content hydrogel totally or substantially free of silicone. A hydrated silicone hydrogel contact lens of... Novartis Ag

Surgical microscope with integrated optical coherence tomography and display systems

An ophthalmic surgical microscope includes a beam coupler positioned along an optical path of the surgical microscope between a first eyepiece and magnifying/focusing optics, the beam coupler operable to direct the OCT imaging beam along a first portion of the optical path of the surgical microscope between the beam coupler... Novartis Ag

Flavivirus replicons

The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by... Novartis Ag

Enhancing performance of a capsulotomy device

The present disclosure provides a capsulotomy device having a unique insertion sleeve configuration comprising beveling and two notches at the distal end of the insertion sleeve. The unique configuration assures that the motion the capsulotomy loop comprising the heating element goes through during deployment from and retraction into the insertion... Novartis Ag

Octreotide depot formulation with constantly high exposure levels

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).... Novartis Ag

Oxazine derivative for use in the prevention of alzheimer's disease in at risk patients

The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of... Novartis Ag

Methods and compositions using klotho variant polypeptides

The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho... Novartis Ag

Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.... Novartis Ag

Extraction of microscope zoom level using object tracking

A method and system for extracting the zoom level of a microscope is disclosed. The method includes capturing a reference image; recording a first zoom level corresponding to a first magnification at which the reference image is captured; capturing a second image; determining a second zoom level by comparing the... Novartis Ag

Method and performing ophthalmic procedures removing undesirable features using laser energy

A method and system perform an ophthalmic procedure on an eye having an optical path from the lens to the retina. An image of at least part of the eye is received in a data processing unit. The image includes the optical path. The data processing unit determines keep out... Novartis Ag

Integrated ophthalmic surgical system

An ophthalmic surgical system includes a chassis comprising a laser source. The system includes a gantry coupled to the chassis. The position of the gantry is adjustable. The system includes a reference interface coupled to the gantry. The reference interface comprises an attachment interface at a distal portion of the... Novartis Ag

Pressure control in phacoemulsification system

A surgical system comprises a pressurized irrigation fluid source with a flexible bag located between two opposing plates. An irrigation line is fluidly coupled to the pressurized irrigation fluid source. A hand piece with an irrigation sleeve is fluidly coupled to the irrigation line. A controller controls the pressurized irrigation... Novartis Ag

Panobinostat dosages for multiple myeloma

Treatment of multiple myeloma with a combination of panobinostat and bortezomib at specified doses adjusted for safety.... Novartis Ag

Aminoheteroaryl benzamides as kinase inhibitors

and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.... Novartis Ag

Isoxazole hydroxamic acid compounds as lpxc inhibitors

This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.... Novartis Ag

Tetracyclic pyridone compounds as antivirals

as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.... Novartis Ag

Novel pyrazolo pyrimidine derivatives and their use as malt1 inhbitors

The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic... Novartis Ag

Toric contact lens having a ballast mark representing a lens identification code

A toric contact lens (1) having a front surface and a rear surface, one of said front and rear surfaces includes a toric optical zone and a lens edge surrounding the contact lens (1). The contact lens further has a ballast axis (3) and includes at least one ballast mark... Novartis Ag

Methods and systems for pulsed illumination

Methods and systems for performing an ophthalmic surgical procedure include pulsed illumination of target tissue. The systems may include an illumination instrument arranged to illuminate tissue at a surgical site during the ophthalmic surgical procedure. A light source provides illumination to the illumination instrument for emission from the illumination instrument... Novartis Ag

Autotaxin inhibitors

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.... Novartis Ag

Process and intermediates for the preparation of nep inhibitors

The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new chemical synthesis route.... Novartis Ag

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on... Novartis Ag

Chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the... Novartis Ag

Reversal binding agents for anti-factor xi/xia antibodies and uses thereof

The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor... Novartis Ag

Method for inspecting an ophthalmic lens using optical coherence tomography

A method for inspecting an ophthalmic lens, such as a contact lens, using Optical Coherence Tomography. The method includes illuminating a sample volume including the lens with a sample light beam which is provided from a light source having a power of at least 2 mW at a wavelength of... Novartis Ag

Optical and digital visualization in a surgical microscope

A surgical microscope may support intraoperative viewing of optical and digital images of a surgical site during surgery. The optical images may be viewed using an optical beam path from an objective lens of the surgical microscope. The digital images may be generated by redirecting or splitting the optical beam... Novartis Ag

Pharmaceutical combinations

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said... Novartis Ag

Optical fiber coupling reliability

Improved optical fiber coupling reliability is realized by improving structures and materials used at the fiber joint. When ceramic ferrules are used at the fiber joint, the penetration of a UV-cured optical adhesive between the ceramic ferrules and the fiber ends is avoided or prevented, while an anti-reflective coating, an... Novartis Ag

Variable working distance microscope

A system and method for a variable working distance microscope is disclosed. The variable working distance microscope includes an eyepiece; a binocular system optically coupled to the eyepiece; a stereo zoom system optically coupled to the eyepiece and the binocular system; and a variable working distance lens system optically coupled... Novartis Ag

Adaptive adjustment of overlay image parameters

Image parameters of an overlay image may be adjusted based on image parameters of an optical image displayed in a surgical microscope. The overlay image may then be displayed with the optical image to a user of the surgical microscope.... Novartis Ag

01/18/18 / #20180018953

Active noise cancellation in an ophthalmic surgical system

Active noise cancellation is employed to address unwanted acoustical noise generated by various equipment associated with an ophthalmic surgical system. Active noise cancellation may be used within a chassis of the ophthalmic surgical system, within an air compressor used with the ophthalmic surgical system, and within a reciprocating surgical probe... Novartis Ag

01/11/18 / #20180008463

Vitrectomy probe with rotary cutter and associated devices, systems, and methods

Systems, apparatuses, and methods of and for an ophthalmic surgical system are disclosed. An ophthalmic surgical system may include a vitrectomy probe having a housing sized and shaped for grasping by a user. The vitrectomy probe may also include a cutter extending from the housing and being sized to penetrate... Novartis Ag

01/11/18 / #20180008611

Method for treating otic infections after tympanostomy tube placement

The present invention relates to methods for treating a microbial infection comprising administering a composition comprising one or more antibiotic compounds to the site of the infection by instilling the composition into the tympanostomy tube. A delivery cannula can be used to instill the composition into the tympanostomy tube.... Novartis Ag

01/11/18 / #20180008706

Methods of treating psoriatic arthritis using il-17 antagonists

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment... Novartis Ag

01/11/18 / #20180009795

Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof

a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.... Novartis Ag

01/11/18 / #20180009801

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.... Novartis Ag

01/11/18 / #20180009889

Antibodies against notch 3

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.... Novartis Ag

01/11/18 / #20180010132

Inhibition of prmt5 to treat mtap-deficiency-related diseases

The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is MTAP-deficient and/or MTA-accumulating and thus amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment... Novartis Ag

01/11/18 / #20180011988

Application unlock using a connected physical device and transfer of data therebetween

According to one embodiment, a system includes a medical device configured to provide a function to a user, communicate via a wireless communication channel with one or more other devices, and send a signal to shift a medical device application from a locked state to an unlocked state. The system... Novartis Ag

01/04/18 / #20180000785

Methods for treating degenerative diseases/injuries

Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Novartis Ag

01/04/18 / #20180000832
01/04/18 / #20180002292

Process for the production of condensed imidazolo derivatives

The present invention relates to a process for providing the compound of formula I, comprising the step of reacting a compound of formula VII with a base in the presence of an alkaline- or alkaline earth metal salt (MX), wherein LG is a leaving group. The presence of an alkaline-... Novartis Ag

01/04/18 / #20180002368

Novel 3' end caps, 5' end caps and combinations thereof for therapeutic rna

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.... Novartis Ag

12/28/17 / #20170367816

Systems and methods for intraocular lens deployment

An intraocular lens (IOL) insertion apparatus may include a handpiece body having a distal tip and a deployment chamber located at a distal end of the handpiece body. The deployment chamber is sized and shaped to hold a folded IOL. The IOL insertion apparatus further includes a deployment system disposed... Novartis Ag

12/28/17 / #20170367817

Intraocular lens delivery device with telescoping plunger

An intraocular lens (IOL) insertion apparatus may include a hand piece body having a distal tip, an IOL folding chamber, and IOL a dwell position, and a telescoping plunger having a first plunger portion and a second plunger portion. The first plunger portion and second plunger portion may be arranged... Novartis Ag

12/28/17 / #20170367818

Iol delivery systems

An intraocular lens (IOL) insertion apparatus includes a handpiece body having a distal tip and a proximal section. The IOL insertion apparatus also includes a folding chamber located within the handpiece body, the folding chamber shaped to fold an IOL advancing through the folding chamber. The IOL insertion apparatus also... Novartis Ag

12/28/17 / #20170367885

Phacoemulsification handpiece with flexible impeller pump

A phacoemulsification system that includes a hand-graspable body and a phacoemulsification needle extending from a distal portion of the body is disclosed herein. The phacoemulsification system may also include an impeller pump carried by the hand-graspable body and configured to convey an aspiration fluid from a surgical site. The impeller... Novartis Ag

12/28/17 / #20170367886

Graphical user interface representing and controlling surgical parameters

Graphical user interface system and method for displaying and controlling a surgical device, such as a device used in phacoemulsfication procedures. A graphical user interface is displayed on a display screen and includes one or more representations of operating parameters, such as aspiration rate, vacuum, and power that are used... Novartis Ag

12/28/17 / #20170368001

Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.... Novartis Ag

12/28/17 / #20170368038

Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and... Novartis Ag

12/28/17 / #20170368044

Pim kinase inhibitor combinations

The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in... Novartis Ag

12/28/17 / #20170368047

Immunomodulation by iap inhibitors

The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating... Novartis Ag

12/28/17 / #20170369473

Pyrrolidine derivatives as angiotensin ii type 2 antagonists

The invention relates to heterocyclic angiotensin II type 2 (AT2) receptor antagonists of formula (I), and pharmaceutically acceptable salts thereof, ((I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof,combinations thereof, and their use as medic-aments, particularly for the treatment of neuropathic or inflammatory... Novartis Ag

12/21/17 / #20170360603

Membrane delamination devices

Various membrane delamination devices for removing proliferative membranes from underling tissues are disclosed herein. In some implementations, the delamination device may include a first shearing part and a second shearing part. One of the first shearing part and the second shearing part may be moveable relative to the other of... Novartis Ag

12/21/17 / #20170362326

Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies

The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.... Novartis Ag

12/14/17 / #20170355677

Synthesis of 2-carboxamide cycloamino urea derivatives

Provided herein are processes and intermediate compounds useful for the preparation of 2-carboxamide cycloamino urea derivatives, and useful intermediates therefore.... Novartis Ag

12/14/17 / #20170355684

Crystalline isoxazole hydroxamic acid compounds

This invention pertains to a crystalline compound of Formula (A) as described herein and compositions containing this crystalline compound, as well as methods of using the compound or pharmaceutical compositions comprising it to treat bacterial infections. The compound and compositions are especially useful to treat Gram negative bacterial infections, including... Novartis Ag

12/14/17 / #20170355762

Il-17 antagonistic antibodies

An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g.... Novartis Ag

12/14/17 / #20170356006

Optimized expression cassette for expressing a polypeptide with high yield

The present invention is based on the finding that the combination of a specific 5′UTR polynucleotide sequence (see SEQ ID NO 1) and the hCD33 secretory leader sequence in an expression cassette for expressing a polypeptide of interest results in a surprisingly better expression level of the polypeptide of interest... Novartis Ag

12/14/17 / #20170356608

Ophthalmic illumination system with controlled chromaticity

An ophthalmic illumination system includes a light source to emit a light beam and a filter comprising a clear region to transmit visible light in the visible spectrum and a first filtered region to transmit visible light in a first spectral range. The filter is arranged within the optical path... Novartis Ag

Patent Packs
12/07/17 / #20170348091

Dual region accommodating intraocular lens devices, systems, and methods

Disclosed herein is an implantable accommodative IOL device for insertion into an eye of a patient, comprising an active region and a passive region. The active region has a first thickness and first refractive index, and the active region comprises an electrically responsive optical lens having variable optical power. The... Novartis Ag

12/07/17 / #20170348294

Use of alpha 7 nicotinic acetylcholine receptor agonists

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.... Novartis Ag

12/07/17 / #20170349650

Immunoglobulins with reduced aggregation

The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.... Novartis Ag

11/30/17 / #20170340733

Combination therapies

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.... Novartis Ag

11/30/17 / #20170342403

Cell surface display of polypeptide isoforms by stop codon readthrough

Also provided are host cells, comprising respectively designed heterologous nucleic acids and methods for producing a polypeptide using respective host cells.... Novartis Ag

11/23/17 / #20170333181

Dual element accommodating intraocular lens devices, systems, and methods

Disclosed herein is an implantable accommodative IOL device for insertion into an eye of a patient, the device comprising an active element and a passive element. The active element has a first thickness and first refractive index, and the active element comprises an electrically responsive optical lens having variable optical... Novartis Ag

11/23/17 / #20170333252

Vitrectomy probe with end tissue cutter and associated devices, systems, and methods

Systems, apparatuses, and methods of and for an ophthalmic surgical system are disclosed. An ophthalmic surgical system may include a vitreous probe having a housing sized and shaped for grasping by a user. The vitreous probe may also include a cutter extending from the housing and being sized to penetrate... Novartis Ag

11/23/17 / #20170333253

Automated viscous fluid control in vitreoretinal surgery

Ophthalmic surgical devices, systems, and methods for automatically controlling the injection or extraction of viscous fluids from a patient's eye are provided. A syringe pump connected with an actuation line and a powered syringe provides pressures for viscous fluid injection or extraction in a vitreous chamber of the eye. A... Novartis Ag

11/23/17 / #20170333368

Paediatric compositions for treating multiple sclerosis

The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-C20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.... Novartis Ag

11/23/17 / #20170333437

Compounds and compositions for the treatment of parasitic diseases

or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite,... Novartis Ag

11/23/17 / #20170334967

Treatment of cancer using gfr alpha-4 chimeric antigen receptor

The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).... Novartis Ag

11/23/17 / #20170335281

Treatment of cancer using chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of... Novartis Ag

11/16/17 / #20170326000

Automated aspiration throttling in vitreoretinal surgery

Ophthalmic surgical devices, systems, and methods for regulating aspiration from a patient's eye are provided. A vacuum pump in fluid communication with an aspiration line provides fluid aspiration from a vitreous chamber of the eye through the aspiration line. A sensor disposed adjacent to or inside the eye determines sensor... Novartis Ag

11/16/17 / #20170326250

Cell proliferation inhibitors and conjugates thereof

The invention further provides pharmaceutical compositions comprising these compounds and immunoconjugates, and compositions comprising the immunoconjugates or compounds with a therapeutic co-agent, and methods to use these compounds, conjugates and compositions for treating cell proliferation disorders.... Novartis Ag

11/16/17 / #20170327552

Peptides and compositions for treatment of joint damage

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.... Novartis Ag

Patent Packs
11/16/17 / #20170327553

Compositions and methods for long acting proteins

The present invention provides peptide tags that can be linked to a therapeutic molecule in order to decrease the clearance of the therapeutic molecule from the synovial joint, thereby increasing its intra-articular half-life.... Novartis Ag

11/09/17 / #20170319062

Fogging prevention for surgical contact lenses

A contact lens for use with a surgical microscope may be equipped with an anti-fogging device to prevent obscuring the view of a surgeon due to condensation during ophthalmic surgery. The anti-fogging device may deliver thermal energy to a surface of the contact lens to heat the contact lens above... Novartis Ag

11/09/17 / #20170319474

Ophthalmic device having therapeutic agent delivery capability and forming same

The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent... Novartis Ag

11/09/17 / #20170320820

Identifying patient response to s1p receptor modulator administration

(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.... Novartis Ag

11/09/17 / #20170320864

Novel heterocyclic derivatives and their use in the treatment of neurological disorders

in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.... Novartis Ag

11/02/17 / #20170312130

Systems and methods for ocular surgery

Ocular surgery may be performed by a variety of systems, processes, and techniques. In certain implementations, a system and a process for ocular surgery may include the ability to draw ocular fluid into a channel of a hand-held pump system and separate the fluid into multiple compressible channels to create... Novartis Ag

11/02/17 / #20170312357

Manufacture of surfactant-containing compositions

Improved methods for the manufacture of pharmaceutical compositions comprising at least one surfactant, involving prefiltration of the surfactant prior to formulation into final products.... Novartis Ag

11/02/17 / #20170312431

Intraocular pressure sensing systems, devices, and methods

An ophthalmic surgical system enabling pressure measurements proximal to the eye may include an illumination probe having a probe tip configured for insertion through an incision in an eye of a patient. The probe tip may include a distal end of an optical fiber, wherein the distal end of the... Novartis Ag

11/02/17 / #20170313765

Direct expression of antibodies

The present invention relates to methods exogenous nucleic acid molecules, such as RNA, that encode an antibody or antigen-binding fragment of an antibody, and optionally encode a cellular modulation factor and/or a potentiation factor. The cellular modulation factor is a factor that results in increased expression of the antibody and/or... Novartis Ag

10/26/17 / #20170304018

Automated intraocular pressure tamponade

An ophthalmic surgical system includes an imaging device configured to acquire a first image of a fundus of an eye and a hemorrhage detecting unit. The hemorrhage detecting unit includes a processor configured to receive the first fundus image from the imaging device, analyze the first fundus image to detect... Novartis Ag

10/26/17 / #20170304226

Dosage regimen of an s1p receptor modulator

S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.... Novartis Ag

10/26/17 / #20170304289

Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis

The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.... Novartis Ag

10/26/17 / #20170304311

Pharmaceutical combinations

A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the... Novartis Ag

10/26/17 / #20170304313

Therapeutic combination for the treatment of cancer

This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or... Novartis Ag

10/26/17 / #20170304439

Methods of treating psoriasis using il-17 antagonists

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.... Novartis Ag

10/26/17 / #20170304443

Combination therapies of egfr inhibitors

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.... Novartis Ag

10/26/17 / #20170305903

Diazepinone derivatives

or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.... Novartis Ag

10/26/17 / #20170306037

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be... Novartis Ag

10/26/17 / #20170306178

Silicone hydrogel lens with a crosslinked hydrophilic coating

The invention is related to a cost-effective method for making a silicone hydrogel contact lens having a crosslinked hydrophilic coating thereon. A method of the invention involves heating a silicone hydrogel contact lens in an aqueous solution in the presence of a water-soluble, highly branched, thermally-crosslinkable hydrophilic polymeric material having... Novartis Ag

10/26/17 / #20170306409

Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation... Novartis Ag

10/26/17 / #20170306416

Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

Cancer biomarkers and methods of using them are disclosed.... Novartis Ag

10/26/17 / #20170307780

Ophthalmic devices for sustained delivery of active compounds

The invention relates to an ophthalmic product which has a capability of delivering a guest material (e.g., a lubricant or a drug) in a time-controlled-releasing manner. The invention also provides a process for making an ophthalmic product of the invention. In addition, the invention provides a method for time-controlled delivery... Novartis Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Novartis Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Novartis Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###